Equibles does not estimate personal net worth.
Get an email with a short summary when Praxis Precision Medicines, Inc. publishes a filing, an earnings call transcript or a press release.
Get PRAX alertsTim Kelly is recorded as CFO at Praxis Precision Medicines, Inc. (PRAX). Tim Kelly has spoken on 4 earnings calls and 2 other investor events across 1 company, most recently for Praxis Precision Medicines, Inc. on August 6, 2026. Praxis Precision Medicines, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Praxis Precision Medicines, Inc. includes Marcio Souza (CEO and Board Member), Timothy E. Kelly (CFO), Timothy Kelly (CFO) and 7 others.
“Thank you for joining today's call where you've heard about the good updates that we have going on. I'll provide a quick summary of our second quarter financials.”
“So when we talk about essential tremor, it is one of the largest movement disorders, a prevalence of roughly 7 million patients in the U.S., about 2% to 3% of the population, and there's never been a drug designed for this population, which is staggering given the size of it.”
“So when we talk about essential tremor, it is one of the largest movement disorders, a prevalence of roughly 7 million patients in the U.S., about 2% to 3% of the population, and there's never been a drug designed for this population, which is staggering given the size of it.”
“I'll provide a quick summary of our first quarter financials. In Q1, our operating expenses were approximately $106 million, with $78 million of that for R&D and the remaining $28 million for SG&A, driven by ramping activities and hiring related to commercial launch preparations.”
“I'll provide a quick summary of our fourth quarter and full-year financial results. 2025 was the year of continued investment into the pipeline while maintaining rigorous financial stewardship.”
Biotechnology · Healthcare
CFO
